scispace - formally typeset
J

Joshua Samuels

Researcher at University of Texas Health Science Center at Houston

Publications -  106
Citations -  5676

Joshua Samuels is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 30, co-authored 93 publications receiving 4011 citations. Previous affiliations of Joshua Samuels include University of Texas at Austin & Drexel University.

Papers
More filters
Journal ArticleDOI

Improved Postoperative Outcomes Associated with Preoperative Statin Therapy

TL;DR: Preoperative statin therapy may reduce postoperative mortality in patients undergoing surgical procedures, however, the statin associated effects on postoperative cardiovascular morbidity are too variable to draw any conclusion.
Journal ArticleDOI

Masked Hypertension Associates with Left Ventricular Hypertrophy in Children with CKD

TL;DR: It is concluded that casual BP measurements alone are insufficient to predict the presence of LVH in children with CKD and the high prevalence of masked hypertension and its association with LVH supports early echocardiography and ambulatory BP monitoring to evaluate cardiovascular risk in childrenWith CKD.
Journal ArticleDOI

Left Ventricular Hypertrophy in Hypertensive Adolescents Analysis of Risk by 2004 National High Blood Pressure Education Program Working Group Staging Criteria

TL;DR: Recommendations that adolescents with stage 2 HTN by casual measurements alone receive medication initially along with therapeutic lifestyle counseling are reasonable, though ambulatory blood pressure monitoring remains a valuable tool for evaluating children with stage 1 HTN, because >10% have white-coat HTN.
Journal ArticleDOI

Fenoldopam Mesylate in Early Acute Tubular Necrosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

TL;DR: Fenoldopam does not reduce the incidence of death or dialysis therapy in intensive care unit patients with early ATN and a larger multicenter trial using separate randomizations for patients with and without diabetes will be needed to determine the efficacy of fenoldo mesylate in specific subpopulations with ATN.